Heart-Saving pills? diabetes drugs tested to shield breast cancer patients from chemo damage

NCT ID NCT07436663

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether two types of diabetes medications—SGLT2 inhibitors and DPP-4 inhibitors—can prevent heart damage caused by the chemotherapy drug doxorubicin in women with breast cancer. About 150 Egyptian women will be randomly assigned to receive one of the drugs or standard care alongside their chemo. The goal is to see if these drugs help keep the heart pumping strongly and reduce the risk of heart failure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm doxorubicin induced cardiomyopathy prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••